FULCRUM THERAPEUTICS

Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences

03 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET

28 Oct 2021 06:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 Oct 2021 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society

20 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer

08 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences

02 Sep 2021 06:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

16 Aug 2021 15:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock

11 Aug 2021 21:09:48 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

10 Aug 2021 15:24:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

10 Aug 2021 06:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

10 Aug 2021 06:00:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET

04 Aug 2021 06:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function

24 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)

21 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

12 May 2021 06:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

07 May 2021 06:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

06 May 2021 06:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer

06 May 2021 06:00:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8:00 a.m. ET

29 Apr 2021 06:00:01 By Nasdaq GlobeNewswire